Yan Jun, Chen Jie, Zhang Shun, Hu Jinhui, Huang Ling, Li Xingshu
School of Pharmaceutical Sciences, Sun Yat-sen University , Guangzhou 510006, China.
J Med Chem. 2016 Jun 9;59(11):5264-83. doi: 10.1021/acs.jmedchem.6b00021. Epub 2016 May 23.
Twenty-nine novel indole-chalcone derivatives were synthesized and evaluated for antiproliferative activity. Among them, 14k exhibited most potent activity, with IC50 values of 3-9 nM against six cancer cells, which displayed a 3.8-8.7-fold increase in activity when compare with compound 2. Further investigation revealed 14k was a novel tubulin polymerization inhibitor binding to the colchicine site. Its low cytotoxicity toward normal human cells and nearly equally potent activity against drug-resistant cells revealed the possibility for cancer therapy. Cellular mechanism studies elucidated 14k arrests cell cycle at G2/M phase and induces apoptosis along with the decrease of mitochondrial membrane potential. Furthermore, good metabolic stability of 14k was observed in mouse liver microsomes. Importantly, 14k and its phosphate salt 14k-P inhibited tumor growth in xenograft models in vivo without apparent toxicity, which was better than the reference compound CA-4P and 2. In summary, 14k deserves consideration for cancer therapy.
合成了29种新型吲哚-查尔酮衍生物,并对其抗增殖活性进行了评估。其中,14k表现出最强的活性,对六种癌细胞的IC50值为3-9 nM,与化合物2相比,活性提高了3.8-8.7倍。进一步研究表明,14k是一种新型的微管蛋白聚合抑制剂,与秋水仙碱位点结合。它对正常人类细胞的细胞毒性较低,对耐药细胞的活性几乎相同,这揭示了其用于癌症治疗的可能性。细胞机制研究表明,14k使细胞周期停滞在G2/M期,并诱导细胞凋亡,同时线粒体膜电位降低。此外,在小鼠肝微粒体中观察到14k具有良好的代谢稳定性。重要的是,14k及其磷酸盐14k-P在体内异种移植模型中抑制肿瘤生长,且无明显毒性,优于参考化合物CA-4P和2。总之,14k值得考虑用于癌症治疗。